Curated news and analysis on clinical trials, drug approvals, and medical research.
Teva said the FDA accepted its New Drug Application for long-acting olanzapine for schizophrenia, with a decision expected later this year. The company also reported Austedo sales of $2.26 billion in 2025 and plans six biosimilar launches in 2026 and 2027.
Tacoma Police are launching DUI enforcement seven days a week, with a focus on evenings, weekends and late-night hours. The effort targets alcohol impairment, pot and “poly-drug use” and is backed by a $215,000 state grant.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
The FDA approved acalabrutinib plus venetoclax for previously untreated CLL/SLL based on phase 3 AMPLIFY data. The fixed 14-month regimen improved progression-free survival versus chemotherapy.
A multicenter retrospective cohort study of 17 patients with type 2 diabetes and end-stage renal disease found injectable semaglutide was associated with descriptive changes in glycemic control and body weight. No cardiovascular deaths, nonfatal myocardial infarctions, or nonfatal strokes were observed during follow-up.
Neurent Medical has closed an oversubscribed €62.5 million Series C financing round for its Neuromark device for chronic rhinitis. The funding will support commercial expansion, broader evidence generation and pipeline development.
The congenital hyperinsulinism pipeline includes 4+ active companies and 4+ therapies across clinical and nonclinical stages. Zealand Pharma advanced dasiglucagon in January 2026, while RZ358 is in Phase III evaluation.
San Diego lab vacancy remains near record highs, with 31% of lab space sitting empty and asking rents falling for a 15th consecutive quarter to $5.55 per square foot. Leasing activity dropped to 223,000 square feet in the first quarter, while a handful of companies expanded or opened facilities in the market.
The largest CAR-T trial for pediatric solid tumors has opened in the US and UK, enrolling up to 60 young patients across four sites. The NexTGen study targets relapsed or refractory cancers and focuses first on safety and feasibility.
The FDA plans to make one study the default for some new drug approvals instead of two robust clinical trials. The shift could have its biggest effect on drugs for common ailments.
Bruker, The Jackson Laboratory, Ribbon Bio, and Human Longevity announced leadership and advisory changes. The updates include Falko Busse's transition at Bruker and new appointments at the other companies.
CAMP4 Therapeutics announced Nasdaq inducement stock option grants for newly hired employees in February and April 2026. The awards covered 51,000 shares in total and vest over four years.
Revolution Medicines said daraxonrasib extended median survival to 13.2 months versus 6.7 months for chemotherapy in a phase 3 pancreatic cancer study. The company plans to seek FDA approval for the KRAS-targeting pill.
Two quantum chemistry studies reported advances in molecular simulation. One used a 24-qubit superconducting processor to simulate water and Amantadine, while another used machine learning to deliver stable orbital-free calculations for larger drug-like molecules.
The FDA approved updated labeling for Vabysmo to allow extended treatment of macular edema following retinal vein occlusion beyond six months. The label update removes the prior 6-month restriction and retains monthly 6 mg intravitreal dosing.
The FDA has announced plans to crack down on active pharmaceutical ingredients used in compounded GLP-1 drugs and warned about the risks of these products. The agency has cited counterfeit products, non-FDA-approved ingredients and more than 1,000 adverse event reports tied to compounded semaglutide and tirzepatide.
AbbVie reported full-year adjusted EPS of $10 and total net revenue of $61.2 billion for 2025. Merit Financial Group raised its fourth-quarter stake in the company to 93,295 shares worth $21.317 million.
The European Commission approved Enflonsia for prevention of RSV lower respiratory tract disease in infants during their first RSV season. Merck also reported new Phase 3 SMART data showing generally consistent second-season safety in high-risk children under 2 years old.
The FDA granted Breakthrough Device Designations to NG-TEST® Candida auris and NG-TEST® Acineto-5®, two rapid assays targeting critical drug-resistant pathogens. Both tests deliver results within 15 minutes and are currently available for Research Use Only while FDA review continues.
Digital drug design tools and AI are gaining ground as drug development timelines run 10 to 14 years and approval rates remain low. Recent work describes broader AI adoption and an information-theoretic predictive model for drug design.
